Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis

Abstract

This study was conducted to determine the prevalence of prolonged neuromuscular symptoms, including fatigue, anosmia, headache, myalgia, and joint pain in COVID-19 survivors hospitalized with mild, moderate, or severe infections worldwide. The search was conducted up to January 30th, 2021 using three databases (PubMed, Scopus, and Web of Science) to identify potentially eligible studies. Data on study characteristics, follow-up characteristics, and severity of COVID-19 during hospitalization were collected in accordance with PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of relevant articles. The estimated prevalence of specific prolonged neuromuscular symptoms and the association between COVID-19 severity and occurrence of prolonged neuromuscular symptoms was analyzed wherever appropriate. Database search yielded 4,050 articles and 22 articles were included for meta-analysis. The estimated prevalence of prolonged fatigue was recorded in 21.2% (95%CI: 11.9%–34.8%) of 3,730 COVID-19 survivors. Persistent anosmia was recorded in 239 of 2,600 COVID-19 survivors (9.7%, 95%CI: 6.1%–15.2%). In 84 out of 2,412 COVID-19 survivors (8.9%, 95%CI: 3.2%–22.6%), prolonged headache was observed. A total of 53 out of 1,125 COVID-19 patients (5.6%, 95%CI: 2.1%–14.2%) complained of persistent myalgia even after being discharged from the hospital. The prevalence of prolonged joint pain was in 15.4% (95%CI: 8.2%–27.2%) of subjects. Due to data scarcity on COVID-19 severity and prolonged neuromuscular symptoms, association analysis could not be conducted. Widespread concern regarding long-term impacts of COVID-19 was raised after several studies reported prolonged symptoms in COVID-19 survivors. Numerous theories have been proposed to address this concern; however, as the research on this pandemic is still ongoing, no explanation is definitive yet. Therefore, follow-up studies in COVID-19 survivors after recovery from COVID-19 are warranted to determine the pathogenesis of prolonged symptoms. PROSPERO registration: CRD42021242332.

Coffee by-products as the source of antioxidants: a systematic review

“…This systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines 33 as previously used elsewhere. 34,35 Articles were included in this review, when the following criteria were fulfilled: 1). The sample was at least coffee husk, coffee silverskin, coffee pulp, coffee parchment, or the cascara (pulp and outer skin); 2).…”

The role of interleukin-22 in lung health and its therapeutic potential for COVID-19

“…Infiltrating monocytes, macrophages, and neutrophils are clearly found in both lungs, accompanied by multinucleated syncytial cells infiltration in the alveoli that characterized by amphiphilic granular cytoplasm, large nuclei, and prominent nucleoli indicating viral cytopathic alters (27)(28)(29)(30)(31). Additionally, myocardial infarction, kidney damage, and persistent symptoms, such as depression, anxiety, palpitations, chest pain, sleep difficulty, dizziness, and weight loss, also represent the pathological features of critically COVID-19 cases (27)(28)(29)(30)(31)(32). The immune profile in COVID-19 patients has been well reviewed, which shows dysfunction in both the innate and adaptive immune (33,34).…”

“…Generally, the pathological feature of COVID-19 is bilateral diffuse alveolar damage with evidence of neutrophil extracellular traps, fibrin thrombi, and activated platelets in the vessels ( 25 , 26 ). Infiltrating monocytes, macrophages, and neutrophils are clearly found in both lungs, accompanied by multinucleated syncytial cells infiltration in the alveoli that characterized by amphiphilic granular cytoplasm, large nuclei, and prominent nucleoli indicating viral cytopathic alters ( 27 – 31 ). Additionally, myocardial infarction, kidney damage, and persistent symptoms, such as depression, anxiety, palpitations, chest pain, sleep difficulty, dizziness, and weight loss, also represent the pathological features of critically COVID-19 cases ( 27 – 32 ).…”

Prevalence of oral manifestations in COVID‐19: A systematic review

“…Noteworthily, persistent long COVID symptoms like anxiety, prolonged depression, chest pain, palpitations, dizziness and hair loss as well as prolonged neuromuscular symptoms (fatigue, anosmia, headache, myalgia and joint pain) are a cause of grave concern in COVID‐19 patients even after two weeks of recovery. 9 , 10 In a systematic review and meta‐analysis, the authors explored the association between delirium and poor prognosis in COVID‐19 patients and suggested that the delirium in older patients can be an important presenting symptom of COVID‐19 implicating poor outcomes and high risk of mortality. 11 …”